{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:08:36Z","timestamp":1779073716652,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Talquetamab is a first\u2010in\u2010class, T\u2010cell\u2013redirecting bispecific antibody targeting GPRC5D, a novel antigen highly expressed on malignant plasma cells with limited expression in normal tissues. Despite advances in treatment, multiple myeloma (MM) remains incurable, and talquetamab offers a promising therapeutic option for patients with relapsed\/refractory MM. By binding to both GPRC5D on myeloma cells and CD3 on T cells, talquetamab induces T\u2010cell activation and subsequent lysis of GPRC5D\u2010expressing cells. The recommended subcutaneous (SC) dosing regimens of talquetamab monotherapy 0.4\u2009mg\/kg QW (preceded by step\u2010up doses of 0.01 and 0.06\u2009mg\/kg) or 0.8\u2009mg\/kg Q2W (preceded by step\u2010up doses of 0.01, 0.06, and 0.4\u2009mg\/kg) were selected based on the totality of safety, efficacy, pharmacokinetic, and pharmacodynamic data. Exposure\u2010response analyses for efficacy and safety further supported the dose selection. In clinical studies, talquetamab demonstrated robust and durable responses in heavily pretreated RRMM patients, with a favorable benefit\u2013risk profile. Common adverse events included cytokine release syndrome, hematologic toxicities, oral adverse events (dysgeusia etc.), and infections, with hematological toxicities being the most common grade 3\u20134 events. During talquetamab treatment, 35.8% (130\/363) of participants developed anti\u2010drug antibodies, including 18.2% (66\/363) with neutralizing antibodies, across both recommended doses, and no clinically meaningful impact of immunogenicity on talquetamab pharmacokinetics, efficacy, or safety was observed. Talquetamab has received accelerated approval (US) and conditional marketing authorization (EU) with further ongoing investigation as monotherapy or in combination regimens across various MM treatment settings.<\/jats:p>","DOI":"10.1111\/cts.70574","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:14:39Z","timestamp":1778728479000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Talquetamab: Mechanism of Action, Clinical, and Translational Science"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9435-1319","authenticated-orcid":false,"given":"Yibo","family":"Wang","sequence":"first","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6143-7755","authenticated-orcid":false,"given":"Jue","family":"Gong","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Au","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-4732","authenticated-orcid":false,"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5085-0682","authenticated-orcid":false,"given":"Dongfen","family":"Yuan","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-4829","authenticated-orcid":false,"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Zhang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3071-8255","authenticated-orcid":false,"given":"Nahor","family":"Haddish\u2010Berhane","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrajeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_9_3_1","first-page":"373","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"95","author":"Michels T. C.","year":"2017","journal-title":"American Family Physician"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(01)00197-X"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529800"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202X.2004.12628.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01018-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70004"},{"key":"e_1_2_9_13_1","volume-title":"TALQUETAMAB Immunogenicity and Impact on Exposure, Efficacy, and Safety: Analyses From Patients With Relapsed\/Refractory Multiple Myeloma in Monumental\u20101","author":"Gong J.","year":"2025"},{"key":"e_1_2_9_14_1","unstructured":"J.Gong Y.Wang S.Lee et\u00a0al. \u201cPharmacokineticand Immunogenicity Results of Talquetamab + Cetrelimab inPatients With Relapsed\/Refractory Multiple Myeloma: Analyses From TRIMM\u20103 \u201d American College of Clinical Pharmacology (ACCP) Annual Meeting2025."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1216"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967676.59550.94"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970472.64690.4e"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","unstructured":"D.Vishwamitra S.Skerget D.Cortes et\u00a0al. \u201cMechanisms of Resistance and Relapse With Talquetamab in Patients With Relapsed\/Refractory Multiple Myeloma From the Phase 1\/2 MonumenTAL\u20101 Study \u201d American Society of Hematology (ASH) Annual Meeting2023.","DOI":"10.1182\/blood-2023-187755"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007625"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71276"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319980-000000000-00000"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01093-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733935"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029360"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T02:56:18Z","timestamp":1779072978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/cts.70574"],"URL":"https:\/\/doi.org\/10.1111\/cts.70574","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70574"}}